2019 Press Releases Communiqués de presse
Sernova Corp Announces Appointment of Deborah Brown to its Board of Directors
Sernova Announces Collaboration to Advance Therapeutic Cell Pouch Technologies for the Treatment of Hypothyroidism
Sernova Announces First Transplantation of Therapeutic Cells in Cell Pouch for the Company Phase I/II U.S. Clinical Study for Diabetes
Sernova Corp Announces First Patient Implanted with Sernova Cell Pouch in a Phase I/II US Clinical Trial for the Treatment of Hypoglycemia Unawareness
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial
Share the news Partagez les nouvelles
Press Release Communiqué de presse - May 21, 2019 21 May, 2019
Sernova Corp Announces Appointment of Deborah Brown to its Board of Directors
May 21, 2019 9:00 a.m. EST
LONDON, ONTARIO – May 21, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage
regenerative medicine company, today announced the appointment of Ms. Deborah Brown to its Board of
Directors.
Ms. Brown has extensive leadership experience with more than 20 years in senior management roles at a
number of pharmaceutical companies and currently serves as a Managing Partner at Accelera Canada Ltd. She
served as President of EMD Serono, a division of Merck KGaA, Executive Vice President at Serono US, General
Manager, Director of Marketing, and Business Unit Director at Serono Canada and Manager, International
Regulatory at Pasteur Merieux Connaught. Ms. Brown is a former Board Chair of Rx&D (now Innovative
Medicines Canada) and as a Director of the Board, oversaw the 100th anniversary of the association and the
launch of the Canadian Innovation Timeline promoting the contributions Canadian researchers have made to
the discovery and advancement of life science research. Ms. Brown is also a former board member of
BIOTECanada. Ms. Brown holds an MBA from Ivey School of Business. She sits on the board of several
corporate and not-for-profit organizations, including Life Sciences Ontario and the Hamilton/Burlington SPCA.
“Deborah’s nomination comes at an important time as we expand the breadth and experience surrounding
Sernova to help support our clinical development programs, regulatory affairs, R&D, and business
development strategy,” said Mr. Frank Holler, Sernova’s Board Chair. “We’d also like to thank Bruce Weber,
who is stepping down as a director, for his positive contributions to Sernova during his seven years as Board of
Director member.”
Management resolutions at the AGM were approved by a majority of shareholders who voted, including the
election of the directors, Frank Holler (chair), James Parsons, Deborah Brown, Jeffrey Bacha, and Philip
Toleikis; approval of the stock option plan and amendments and approval of Davidson and Co. LLP as
Sernova’s auditor. Additionally, the TSX Venture Exchange (the “Exchange”) has accepted the Plan for filing, as
approved by shareholders at the AGM.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 30, 2019 30 April, 2019
Sernova Announces Collaboration to Advance Therapeutic Cell Pouch Technologies for the Treatment of Hypothyroidism
Co-investigators, Dr. Sam Wiseman of the University of British Columbia and Sernova Corp awarded the
prestigious Transplant Research Foundation of British Columbia Venture Grant
April 30, 2019; 9:00 a.m. EST
LONDON, ONTARIO – April 30, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company announced today a collaboration with the University of British Columbia’s, Dr.
Sam Wiseman for development of a Cell Therapy-based Program for the treatment of hypothyroidism. This
collaboration is funded by a Transplant Venture Grant awarded by the Transplant Research Foundation (TRF)
of British Columbia.
“The only current option for treatment of patients following thyroidectomy, to ensure avoidance of
hypothyroidism, is administration of life-long daily thyroid medication, with intermittent blood testing and
adjustment of medication dosing,” said Dr. Sam Wiseman, thyroid surgeon and researcher, and the Director of
Research in the Department of Surgery at Providence Healthcare in Vancouver. “We hypothesize that through
transplantation into Sernova’s vascularized Cell Pouch, the function of the thyroid gland may be preserved, and
dependence on thyroid medication avoided. This approach is exciting because it could offer patients a cell
therapy option for preservation of their gland function.”
According to the American Thyroid Association (ATA), 20 million Americans currently live with thyroid disease,
and 12% of Americans will develop a thyroid condition during their lifetime. The thyroid gland produces and
secretes thyroid hormone that is essential for life because it serves to regulate the entire body’s metabolism.
The thyroid gland affects all critical body functions including heart rate, energy levels, and the rate at which
energy is produced from nutrients. Loss of thyroid function, or hypothyroidism, may occur spontaneously, or
due to partial or complete removal of the thyroid gland by operation (thyroidectomy).
“The cell-based treatment of hypothyroid disease following thyroidectomy represents a third significant clinical
application including type-1 diabetes and hemophilia further validating Sernova’s Cell Pouch platform
technologies in significant potential markets,” said Dr. Philip Toleikis, President and CEO of Sernova. “The
development of a regenerative medicine approach for these chronic diseases is becoming a reality. In this case
of thyroid disease, successful transplantation of thyroid tissue into Sernova’s cell pouch would represent a
major advance in treatment of this very common problem.”
Thyroidectomy is commonly performed for cancer diagnosis or treatment, as well as for treatment of benign
(non-cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000
thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation
will be diagnosed with benign disease after their operation. Patients with Grave’s disease and thyroid nodules
undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid
hormone medication. Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be
effective; however, patients often suffer from side effects including weight gain, depression, headaches, and
cardiovascular disease, with resultant negative impact on quality of life, and costs to the healthcare system.
Sernova’s approach in the treatment of hypothyroid disease is to transplant healthy thyroid cells of patients
undergoing thyroidectomy into the pre-implanted vascularized Cell Pouch. Currently, pre-clinical proof-of-
concept work is underway. The collaboration will accelerate Sernova’s research efforts and set the stage for the
preparation of a regulatory submission for future clinical assessment of people suffering from hypothyroid
disease with the aim to preserve thyroid function and improve patient quality of life.
In other news, Sernova has been invited to present at the 2019 Bloom Burton & Co. Healthcare Investment
Conference, being held at the Metro Toronto Convention Centre, in Toronto on April 30 and May 1st. Sernova
President and CEO, Dr. Philip Toleikis will speak to its latest corporate presentation and US Phase I/II Human
Clinical Trial at 4:00 PM EDT, on Wednesday, May 1st.
About Sernova Corp.
Sernova, Corp., (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive
platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary
focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes,
hemophilia A and thyroid disease. Sernova is developing regenerative medicine therapeutic technologies using
a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and
stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases
such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases such as
hypothyroid disease treated through replacement of proteins or hormones missing or in short supply within the
body.
For further information contact:
United States
Danny Matthews,
Senior Associate, Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Corporate Communications
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of pre-clinical
results and clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 11, 2019 11 April, 2019
Sernova Announces First Transplantation of Therapeutic Cells in Cell Pouch for the Company Phase I/II U.S. Clinical Study for Diabetes
April 11, 2019, 9:00 a.m. EDT
LONDON, ONTARIO – April 11, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company today announced the first Cell Pouch™ transplant of insulin-producing cells in
its U.S. Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch for Clinical Islet
Transplantation in type 1 diabetes.
“Sernova’s Cell Pouch technologies are positioned to provide the most severe patients with improved, long
term options to manage their diabetes,” said Dr. Piotr Witkowski, Clinical Trial Principal Investigator and
Director of the Pancreatic Islet Transplant Program at the University of Chicago. “The current standard of care,
involves islet transplants into the portal vein which has significant limitations including the development of an
immediate blood-mediated inflammatory reaction (IBMIR), limited supply of donor organs and the challenges in
isolating and obtaining a consistent quality of islet preparations.”
In accordance with the study protocol, the Cell Pouch was implanted prior to transplant of purified islets. This
procedure enables the development of vascularized tissue chambers and provides an interval for patient
stabilization on standard immune protection medications. Prior to transplantation, the Cell Pouch was
assessed for safety. A Sentinel Pouch, a small monitoring device, was also transplanted with islets. In
accordance with the protocol the Sentinel Pouch will be removed approximately 90 days post-transplant to
assess islet survival as an interim indicator of efficacy.
“Sernova’s Cell Pouch provides a non-fibrosing, vascularized environment for the transplantation of therapeutic
cells, to enhance the curative potential of islet transplantation and other cell therapies,” said Dr. Philip Toleikis,
President and CEO of Sernova. “We are thrilled with Dr. Witkowski’s progress as well as his decision to move
forward with transplantation based on his analysis of the safety and vascularization of the Cell Pouch.”
“This important clinical milestone advances our Cell Pouch technologies as a valuable enabling foundation for
cell therapies across a range of indications including type 1 diabetes, hemophilia and thyroid disease,” added
Dr. Toleikis.
The Company is expecting to report preliminary safety data from Sernova’s clinical study in the first half of
2019 and preliminary efficacy data in the second half of 2019.
About the Study
The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. Participants
are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the
Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict
release criteria, is transplanted into the Cell Pouch.
A sentinel pouch will be removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate the safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.
About Hypoglycemia Unawareness and Diabetes
Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune
system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body
use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on
insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with
multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1
diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health
complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop
in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.
About the Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the
long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming
highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release
proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to
provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to
provide a biologically compatible environment for insulin-producing cells in humans.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 11, 2019 11 February, 2019
Sernova Corp Announces First Patient Implanted with Sernova Cell Pouch in a Phase I/II US Clinical Trial for the Treatment of Hypoglycemia Unawareness in Subjects with Type 1 Diabetes
February 11, 2019; 9:00 a.m. EST
LONDON, ONTARIO – February 11, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company today announced the first patient implanted with Sernova’s Cell Pouch™ in the
Phase I/II clinical trial evaluating the safety and efficacy of Sernova’s Cell Pouch™ for Clinical Islet
Transplantation in type 1 diabetes.
“Islet transplantation has shown success as a therapeutic option for treating patients with hypoglycemia
unawareness; the most unstable, high-risk form of type 1 diabetes. Given the limited supply of donor islet
cells, it is imperative to develop approaches that capitalize on a more efficient use of donor islet cells,” said Dr.
Piotr Witkowski principal investigator and Director of the Pancreatic and Islet Transplant Program at University
of Chicago School of Medicine. “We believe Sernova’s Cell Pouch creates a vascularized environment, rich in
microvessels that will allow robust engraftment and extended survival of the transplanted islet cells. We hope
this will result in the need for fewer transplants per patient and, ultimately, create a long-term treatment option
for patients suffering from hypoglycemic unawareness.”
Cell Pouches, including, small sentinel pouches were implanted. Following development of the vascularized
tissue chambers, and stabilization on immune protection medications, the Cell Pouch will be transplanted with
donor islet cells. Approximately 90-days after transplant, small sentinel devices are removed to evaluate islet
survival as an initial efficacy endpoint.
“This important clinical milestone represents an exciting time at Sernova as we pursue safe, effective, and
innovative regenerative medicine treatments for patients with hypoglycemia unawareness in type 1 diabetes,”
said Dr. Philip Toleikis, President and CEO of Sernova Corp. “We are confident this US clinical trial will support
and add important data to the positive pre-clinical results of our small and large diabetes animal models, and
our first-in-human trial with Health Canada. It will also contribute to the development of broader applications
for the Cell Pouch including our diabetes stem cell technologies and additional indications.”
The Company is expecting to report preliminary safety data from Sernova’s clinical study in the first half of
2019 and preliminary efficacy data in the second half of 2019.
About the Study
The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. Participants
are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the
Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict
release criteria, is transplanted into the Cell Pouch.
A sentinel pouch will be removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939 . For
more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact
(773) 702-2504.
About Hypoglycemia Unawareness and Diabetes
Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune
system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body
use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on
insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with
multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1
diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health
complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop
in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.
About the Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the
long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming
highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release
proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to
provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to
provide a biologically compatible environment for insulin-producing cells in humans.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States: Danny Matthews Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 30, 2019 30 January, 2019
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board
Sernova Adds Scientific Advisory Board Expertise as it Broadens its Therapeutic Cell Therapy Applications for
Rare Blood Diseases
January 30, 2019 9:00 a.m. EST
LONDON, ONTARIO – January 30, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage
regenerative medicine company, today announced the appointment of Dr. David Lillicrap, M.D., FRCPC to its
Scientific Advisory Board (SAB).
Dr. David Lillicrap is Associate Head, Research, and Professor in the Department of Pathology and Molecular
Medicine at Queen's University at Kingston, Ontario, Canada. He holds a Tier 1 Canada Research Chair (CRC)
in Molecular Hemostasis and is a past Career Investigator of the Heart and Stroke Foundation of Ontario. In
2013, he was elected to the Fellowship of the Royal Society of Canada. Dr. Lillicrap serves as a member of the
Medical Advisory Board of the World Federation of Hemophilia. He is a member of the Council of the
International Society on Thrombosis and Haemostasis (ISTH), is a past Chair of ISTH’s Scientific and
Standardization Committee and is Co-Editor-in-Chief of the Society’s journal, the Journal of Thrombosis and
Haemostasis. Dr. Lillicrap has also been a SAB member of the Horizon 2020 HemAcure program developing a
personalized medicine approach for treatment of hemophilia of which Sernova is partner. He is an
internationally recognized expert on the molecular basis of common inherited bleeding disorders.
“We are pleased to welcome David to Sernova’s Scientific Advisory Board,” said Dr. Philip Toleikis President
and CEO Sernova Corp. “Dr. Lillicrap’s internationally recognized leadership in hematology and novel cell and
gene therapy-based applications will be instrumental as we expand the breadth and experience of our Scientific
Advisory Board in support of Sernova’s hemophilia and other rare disease programs.”
As a Canada Research Chair in Molecular Hemostasis, his program of research focuses on the molecular basis
of the hemostatic system (coagulation), with a particular emphasis on the commonest inherited bleeding
disorders, hemophilia, and von Willebrand disease. During his tenure as a Canada Research Chair, Dr.
Lillicrap’s group has achieved several research accomplishments including the establishment of a national
reference laboratory for the genetic diagnosis of inherited bleeding disorders. His research interests focus on
three key areas including von Willebrand factor pathobiology, factor VIII immunology and the evaluation of
novel gene, and cell-based strategies for the treatment of hemophilia.
About the Cell Pouch System
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-
term survival and function of immune protected therapeutic cells. The device is designed to incorporate with
tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells
which then release proteins and hormones as required to treat disease. The device along with therapeutic cells
has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has
been proven to provide a biologically compatible environment for insulin-producing cells in humans. Within the
Horizon 2020 HemAcure program corrected human cells from subjects with Hemophilia A have been shown to
engraft within the Cell Pouch, produce Factor VIII and improve blood clotting in a preclinical model of
hemophilia A.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 28, 2019 28 January, 2019
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
January 28, 2019 6:00 a.m. EST
LONDON, ONTARIO – January 28, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-
stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO will present
the latest company overview and is invited to participate on the Diabetes Panel at NobleConXV — Noble
Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Fla., on Monday
January 28th at 11:00 a.m. Eastern Time.
The panel will cover a broad spectrum of interests involving diabetes including the discovery and
commercialization of novel diabetes therapeutics and diagnostics, diabetes research, as well as nutrition and
awareness. Included on the panel are Dr. Camillo Ricordi, Director of the Diabetes Research Institute; Dr.
Michael Castagna, CEO of MannKind Corporation; Steve Perrin, Ph.D., CEO and Founder of Anelixis
Therapeutics; William L. Rust, Ph.D., CEO and Founder of Seraxis; Michael Fox of DugalHealth; Martin Beland,
VP Marketing and Strategic Development of Inolife Sciences; Steve Glover, CEO of Variant Pharmaceuticals;
and Dr. Philip Toleikis, Ph.D., President & CEO of Sernova Corp.
A video webcast of the presentation will be available the following day on the company's website
www.sernova.com and as part of a complete catalog of presentations available at Noble Capital Markets’
Conference website (http://nobleconference.com) as well as on the new investor portal created by Noble called
Channelchek (http://www.channelchek.com).
About Sernova, Corp
Sernova, Corp., (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive
platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary
focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes,
hemophilia A and thyroid disease. Sernova is developing regenerative medicine therapeutic technologies using a
medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and
stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases
such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through
replacement of proteins or hormones missing or in short supply within the body.
For further information contact:
Danny Matthews, Senior Associate
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray, Corporate Communications
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 17, 2019 17 January, 2019
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial
January 17, 2019 9:00 a.m. EST
LONDON, ONTARIO – January 17, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company today announced the enrollment of the first three of seven subjects in its Phase
I/II trial of Sernova’s Cell Pouch™ for Clinical Islet Transplantation in type 1 diabetes.
“We are pleased to report we are on track with patient enrollment in the Sernova Cell Pouch study for type 1
diabetes,” stated Dr. Piotr Witkowski, principal investigator and Director of the Pancreatic and Islet Transplant
Program at University of Chicago School of Medicine. “The Cell Pouch System is designed to improve the
quality of life of people with diabetes and this milestone marks an important step towards building further
validation of Sernova’s innovative approach to diabetes treatment.”
Sernova is expecting to report preliminary safety data from this landmark clinical study in the first half of 2019
and preliminary efficacy data in the second half of 2019.
About the Study
The FDA allowed protocol is a Phase I/II non-randomized, open label, single arm, company-sponsored trial,
where up to seven diabetic subjects with hypoglycemia unawareness enroll into the study under informed
consent. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation
into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures including
reduction in severe hypoglycemic events and HbA1c as well as survival of islets following transplant into the
Cell Pouch.
Study subjects will receive Sernova’s Cell Pouches including a small sentinel device implanted under the skin.
Following a defined period to allow for the development of vascularized tissue chambers within the Cell Pouch,
subjects will be stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, will
be transplanted into the Cell Pouch.
The sentinel Cell Pouch will be removed after approximately 90 days to allow for an early assessment of islet
survival in the device. Subjects will be followed for additional safety and efficacy measures for approximately
six months. At this point, a decision will be made with regard to the transplant of a second dose of purified
islets. Patients will then be further followed to assess safety and efficacy for up to one year.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact (773)
702-2504.
About Diabetes
Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune
system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body
use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on
insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with
multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1
diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health
complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop
in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.
About the Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-
term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly
vascularized tissue chambers for the transplantation and function of therapeutic cells which then release
proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to
provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to
provide a biologically compatible environment for insulin-producing cells in humans.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Contact Us Contactez-nous
Business
development
Développement
des affaires
Dr. Philip Toleikis
Sernova Corp.
1.519.858.5184
info@sernova.com
Investor
relations
Communication
d'entreprise
Danny Matthews
Solebury Trout
1.646.378.2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Corporate
communications
Communication
d'entreprise
Dominic Gray
Sernova, Corp.
1.519.858.5126
info@sernova.com
About UsL'entreprise
Company OverviewPrésentation de l'entreprise
LeadershipDirection
PartnersLes partenaires
Company MilestonesJalons de l'entreprise
Corporate GovernanceGouvernance d'Entreprise
TechnologyTechnologie
Regenerative MedicineMédecine régénérative
Cell Pouch System™Cell Pouch System™
Immune Protection TechnologyImmuno-Protection
IndicationsLes Indications
Therapeutic PipelinePipeline Thérapeutique
Clinical StudiesEtudes cliniques
PressPresse
Featured NewsNouvelles
Press ReleasesCommuniqués de presse
Latest UpdatesDernières mises à jour
News Dispatch ServiceService de Distribution de Nouvelles
InvestorInvestisseur
Financial ReportsRapports Financiers
EventsÉvénements
Analyst Coverage Couverture d'analyste
Stock PricePrix de l'action
About Sernova.com A propos de Sernova.com
Sernova Corp (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, hemophilia A and thyroid disease. Sernova Corp (TSX-V: SVA) est une société en phase clinique (US FDA; Santé Canada) développant des applications thérapeutiques afin de traiter les maladies chroniques grâce à une approche régénérative. L’objectif principal de Sernova est de développer des technologies pour le traitement des patients atteints de diabète insulino-dépendant (T1), d’hémophilie A et de maladie de la glande thyroïde.
Please read our Legal Notice and Privacy Policy which includes information about Disclaimers and Terms of Use. Veuillez lire notre notice légale et notre politique de confidentialité, qui comprennent des informations sur les clauses de non-responsabilité et les conditions d'utilisation.
Career OpportunitiesOpportunités de carrière
See our latest job posting and long-term career opportunities: Voir nos dernières offres d'emploi et opportunités de carrière à long terme:
Career Opportunities pagePage web Opportunités de carrière
Follow us Suivez nous
All content is copyright
Tout le contenu est copyright
© 2001 - 2019 Sernova, Corp.
All content is copyright Tout le contenu est copyright © 2001 - 2019 Sernova, Corp.